Latrunculin A supplemented vitrification medium
OtherVitrification of human oocyte in medium supplemented with Latrunculin A
NCT Number: NCT03678571
Using cytoskeleton Stabilizer the Latrunculin A would improve the outcome of oocyte vitrification
Looking for future studies?
Notify Me18 year–42 year
Female
Interventional
Not applicable
Qena Fertility Center, Qina, Qena Governorate, Egypt
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
-
Vitrification of human oocyte in medium supplemented with Latrunculin A
Time frame: 6 days after thawing
Time frame: 6 days of culture
Time frame: 6 days of culture
Number of formed blastocyst and high-quality blastocysts per fertilized oocytes
Time frame: 6 days of culture
Number of utilized embryos per fertilized oocytes
Time frame: three months
Number of pregnant women with fetal pulsation per recruited cycles
Time frame: 12 months
Ibn Sina Hospital
Other Gov
Latrunculin A for Oocyte Vitrification
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06659692
Genital Diseases, Infertility
Toronto, Ontario, Canada
View Trial DetailsNCT06924437
Abnormal Uterine Bleeding (AUB), Endometrial Polyp
Sohag, Egypt
View Trial DetailsNCT01511588
Adolescents, Amenorrhea
Bethesda, Maryland, United States
View Trial DetailsNCT07399535
Adnexal Diseases, Cysts
Karachi, Sindh, Pakistan
View Trial Details